https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53768 Wed 28 Feb 2024 15:52:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53776 Wed 28 Feb 2024 15:31:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45142 Wed 26 Oct 2022 15:43:14 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47693 Wed 25 Jan 2023 08:42:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36361 Wed 24 May 2023 12:19:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33534 Wed 23 Feb 2022 16:05:22 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34498 ref). Dosimetric endpoints were based on dose-volume histograms calculated from the CT_ref and the pCTs for various volumes of interest and on 3-dimensional gamma analyses. The PBM uncertainties were compared with those of the ABM and BDM. Results: The mean absolute error and mean error obtained from the PBM were 41.1 and –1.1 Hounsfield units. The PBM dose-volume histogram differences were 0.7% for prostate planning target volume V_95%, 0.5% for rectum V_70Gy, and 0.2% for bladder V_50Gy. Compared with ABM and BDM, PBM provided significantly lower dose uncertainties for the prostate planning target volume (70-78 Gy), the rectum (8.5-29 Gy, 40-48 Gy, and 61-73 Gy), and the bladder (12-78 Gy). The PBM mean gamma pass rate (99.5%) was significantly higher than that of ABM (94.9%) or BDM (96.1%). Conclusions: The proposed PBM provides low uncertainties with dose planned on CTref. These uncertainties were smaller than those of ABM and BDM and are unlikely to be clinically significant.]]> Wed 23 Feb 2022 16:03:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51701 Wed 21 Feb 2024 14:59:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32834 Wed 19 Jan 2022 15:17:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42282 Wed 16 Aug 2023 14:37:30 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47094 Wed 14 Dec 2022 09:37:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40374 Wed 13 Mar 2024 08:55:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32516 Wed 13 Jun 2018 11:02:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24445 Wed 11 Apr 2018 16:51:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16710 Wed 11 Apr 2018 14:46:26 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21638 Wed 11 Apr 2018 12:44:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30808 Wed 11 Apr 2018 12:31:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28129 3. The external body deformation caused a mean dose reduction of 0.6 ± 0.3 Gy, while the coverage reduced by 22% ± 13% and 27% ± 6% in V₉₈ and V₁₀₀, respectively. A dedicated MR simulation setup for prostate radiotherapy is essential to ensure the agreement between planning anatomy and treatment anatomy. The image signal was reduced after applying the coil mount, but no significant effect was found on prostate contouring.]]> Wed 11 Apr 2018 09:52:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30452 Wed 11 Apr 2018 09:43:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53707 Wed 10 Jan 2024 11:03:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44516 95% of fractions were successfully delivered. The secondary outcomes were (1) the improvement in beam-target geometric alignment, (2) the improvement in dosimetric coverage of the prostate and avoidance of critical structures, and (3) no acute grade ≥3 genitourinary or gastrointestinal toxicity. Results: All 858 planned fractions were successfully delivered with MLC tracking, demonstrating the primary outcome of feasibility (P < .001). MLC tracking improved the beam-target geometric alignment from 1.4 to 0.90 mm (root-mean-square error). MLC tracking improved the dosimetric coverage of the prostate and reduced the daily variation in dose to critical structures. No acute grade ≥3 genitourinary or gastrointestinal toxicity was observed. Conclusions: Electromagnetic-guided MLC tracking radiation therapy for prostate cancer is feasible. The patients received improved geometric targeting and delivered dose distributions that were closer to those planned than they would have received without electromagnetic-guided MLC tracking. No significant acute toxicity was observed.]]> Wed 09 Nov 2022 10:02:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24121 Wed 09 Nov 2016 16:28:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33706 Wed 09 Mar 2022 16:04:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31828 Wed 09 Mar 2022 16:00:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33370 Wed 09 Feb 2022 15:55:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25149 Wed 09 Feb 2022 15:54:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30211 Wed 09 Feb 2022 15:53:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51088 Wed 06 Mar 2024 15:14:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33216 Wed 04 Sep 2019 12:18:00 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45588 Wed 02 Nov 2022 10:40:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33939 Wed 02 Mar 2022 14:26:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53314 Tue 21 Nov 2023 12:37:09 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47980 Tue 21 Mar 2023 16:56:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48330 Tue 14 Mar 2023 16:54:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51626 Tue 12 Sep 2023 15:40:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46010 Tue 08 Nov 2022 17:28:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42275 Tue 07 Nov 2023 11:20:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34963 Tue 03 Sep 2019 17:58:01 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30986 Tue 01 May 2018 09:16:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51315 Thu 31 Aug 2023 14:30:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24585 Thu 29 Nov 2018 10:14:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34511 0.1cc, D_1cc, D_2cc and D_10cc were calculated in two ways. (i) Parameter-adding: the EBRT DVH parameters (or the EBRT prescription dose) were added to the unregistered HDR-BT DVH parameters. (ii) Distribution-adding: the parameters were extracted after the EBRT doses were 3D-summed with the registered HDR-BT doses. Resulting differences between the parameters were investigated. Results: The D_0.1cc, D_1cc and D_2cc from parameter-adding were 21.3% (P < 0.001), 6.3% (P < 0.001) and 3.5% (P < 0.001) smaller than those from distribution-adding. The D_10cc was 2.2% (P=0.015) larger for distribution-adding. Conclusion: Distribution-adding was confounded by unsystematic inter/intra-observer rectum-contouring errors and registration accuracy near the anterior rectal wall. Consequently, clinical use of distribution-adding to assess rectal doses requires careful contour and registration evaluation.]]> Thu 28 Oct 2021 13:04:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33342 Thu 28 Oct 2021 13:04:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36284 Thu 27 Jan 2022 15:57:32 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46465 n=388) and CHHiP (n=241) trials onto the same exemplar and repeating the tests on each of these data sets, and on all three datasets combined. Results: Voxel-based Cox regression and permutation dose difference testing revealed regions where increased dose was correlated with gastrointestinal toxicity. Grade=2 RB was associated with posteriorly extended lateral beams that manifested high doses (> 55 Gy) in a small rectal volume adjacent to the clinical target volume. A correlation was found between grade=2 tenesmus and increased low-intermediate dose (~25 Gy) at the posterior beam region, including the posterior rectum and perirectal fat space (PRFS). Conclusions: The serial response of the rectum with respect to RB has been demonstrated in patients with posteriorly extended lateral beams. Similarly, the parallel response of the PRFS with respect to tenesmus has been demonstrated in patients treated with the posterior beam.]]> Thu 24 Nov 2022 15:46:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51846 Thu 21 Sep 2023 09:27:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38734 Thu 21 Jul 2022 09:53:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44701 Thu 20 Oct 2022 15:58:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38728 Thu 20 Jan 2022 13:36:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49451 null (NSG) mice to incorporate two levels of humanization; the primary tumor and TME, and the secondary metastatic bone organ. Bioluminescent imaging, histology, and immunohistochemistry were used to study metastasis of human PC-3 and LNCaP PCa cells from the prostate to tissue-engineered bone. Here we show pre-seeding scaffolds with human osteoblasts increases the human cellular and extracellular matrix content of bone constructs, compared to unseeded scaffolds. The humanized prostate TME showed a trend to decrease metastasis of PC-3 PCa cells to the tissue-engineered bone, but did not affect the metastatic potential of PCa cells to the endogenous murine bones or organs. On the other hand, the humanized TME enhanced LNCaP tumor growth and metastasis to humanized and murine bone. Together this demonstrates the importance of the TME in PCa bone tropism, although further investigations are needed to delineate specific roles of the TME components in this context.]]> Thu 18 May 2023 09:45:06 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36411 Thu 17 Jun 2021 16:12:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34741 Thu 17 Feb 2022 09:29:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30963 Thu 17 Feb 2022 09:26:28 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43246 Thu 15 Sep 2022 10:17:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40019 n = 388) and CHHiP (up to n = 247) trials onto the same exemplar and repeating the voxel-based tests on each of these data sets. All three datasets were then combined, and the tests repeated. Results: Voxel-based Cox regression and multiple comparison permutation dose difference testing revealed regions where increased dose was correlated with genitourinary toxicity. Increased dose in the vicinity of the membranous and spongy urethra was associated with dysuria for all datasets. Haematuria was similarly correlated with increased dose at the membranous and spongy urethra, for the RADAR, CHHiP, and combined datasets. Some evidence was found for the association between incontinence and increased dose at the internal and external urethral sphincter for RADAR and the internal sphincter alone for the combined dataset. Incontinence was also strongly correlated with dose from posterior oblique beams. Patients with fields extending inferiorly and posteriorly to the CTV, adjacent to the membranous and spongy urethra, were found to experience increased frequency. Conclusions: Anatomically-localized dose-toxicity relationships were determined for late genitourinary symptoms in the urethra and urinary sphincters. Low-intermediate doses to the extraprostatic urethra were associated with risk of late dysuria and haematuria, while dose to the urinary sphincters was associated with incontinence.]]> Thu 14 Jul 2022 13:55:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35516 Thu 11 Feb 2021 09:22:18 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40626 Thu 11 Aug 2022 11:20:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36717 Thu 09 Dec 2021 11:03:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37248 50 = 116.7 Gy and m = 0.23; n was fixed to 0.3, based on numerical optimization of the likelihood. The calibration plot showed a good agreement between the observed toxicity and the probability predicted by the model, confirmed by bootstrapping. For the external validation, the calibration plot showed that the observed toxicity obtained with the RADAR patients was well-represented by the fitted LKB model parameters. When patients were stratified by the use of AD TD₅₀ decreased when AD was not present. Conclusions: Lyman–Kutcher–Burman model parameters were fitted to the risk of urethral stricture and externally validated with an independent cohort, to provide guidance on urethral tolerance doses for patients treated with a HDRB boost. For patients that did not receive AD, model fitting provided a lower TD₅₀ suggesting a protective effect on urethra toxicity.]]> Thu 09 Dec 2021 11:03:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35014 Thu 09 Dec 2021 11:01:40 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33473 Thu 09 Dec 2021 11:01:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49877 Thu 08 Jun 2023 15:49:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51488 Thu 07 Sep 2023 10:52:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51485 Thu 07 Sep 2023 10:51:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35067 853.0–973.9 μg/l). Among five analyzed genetic variants, rs11568818 in MMP-7 appeared to be correlated with 2-fold increased prostate cancer risk (OR = 2.39, 95% CI = 1.19–4.82, p = 0.015). Conclusion: Our results suggest a significant correlation of higher serum zinc levels with the diagnosis of prostate cancer. The polymorphism rs11568818 in MMP-7 gene was also associated with an increased prostate cancer risk in Poland.]]> Thu 04 Nov 2021 10:38:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29967 Thu 03 Feb 2022 12:22:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33046 Thu 03 Feb 2022 12:19:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25777 1. DVHs of anorectum were reduced to equivalent uniform dose (EUD). The best-value of the volume parameter n was determined through numerical optimization. Association between EUD/clinical factors and the endpoints was investigated by logistic analyses. Likelihood, Brier-score and calibration were used to evaluate models. External calibration was also carried out. Results: 4% of patients (45/1122) reported mean stool frequency grade >1; grade ≥2 rectal pain was present in the TROG 03.04 RADAR population only (21/677, 3.1%): for this endpoint, the analysis was limited to this population. Analysis of DVHs highlighted the importance of mid-range doses (30-50Gy) for both endpoints. EUDs calculated with n=1 (OR=1.04) and n=0.35 (OR=1.06) were the most suitable dosimetric descriptors for stool frequency and rectal pain respectively. The final models included EUD and cardiovascular diseases (OR=1.78) for stool frequency and EUD and presence of acute gastrointestinal toxicity (OR=4.2) for rectal pain. Conclusion: Best predictors of stool frequency and rectal pain are consistent with findings previously reported for late faecal incontinence, indicating an important role in optimization of mid-range dose region to minimize these symptoms highly impacting the quality-of-life of long surviving patients.]]> Thu 03 Feb 2022 12:18:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32780 Thu 03 Feb 2022 12:18:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33474 Thu 03 Feb 2022 12:18:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42724 Thu 01 Sep 2022 13:18:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46813 Thu 01 Dec 2022 10:36:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21004 74 years: HR=2.73, 95% CI: 2.55-2.93), and those living in inner regional (HR=1.11, 95% CI: 1.04-1.18) or rural areas (HR=1.24, 95% CI: 1.14-1.36) or more disadvantaged areas (middle tertile: HR=1.09, 95% CI: 1.02-1.16; most disadvantaged: HR=1.12, 95% CI: 1.04-1.19). The risk of developing metastatic disease decreased over calendar time (adjusted HR=0.98, 95% CI: 0.97-0.99 per year). Conclusions: After a median follow-up of 6.8 years more than 1 in 5 men diagnosed with non-metastatic prostate cancer developed distant metastases. This estimate of the overall risk of developing metastatic disease in the population, and the geographical disparities identified, can inform the planning of required cancer services.]]> Sat 24 Mar 2018 07:50:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29325 Sat 24 Mar 2018 07:34:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27200 Sat 24 Mar 2018 07:31:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26054 Sat 24 Mar 2018 07:31:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26639 Sat 24 Mar 2018 07:26:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26742 Sat 24 Mar 2018 07:24:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22835 1 timepoints. Associations at a single timepoint were found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular condition and smoking status. Conclusions: The prevalence and incidence analysis provide a complementary view for urinary symptom prediction. Sustained impacts across time points were found for several factors while some associations were not repeated at different time points suggesting poorer or transient impact.]]> Sat 24 Mar 2018 07:16:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48220 Sat 11 Mar 2023 12:36:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43577 Skin detectors were an effective tool for measuring dose delivered to the anterior rectal wall in real time during prostate SBRT boost treatments for the purpose of both ensuring the rectal doses remain within acceptable limits during the treatment and for the verification of final rectal doses.]]> Mon 26 Sep 2022 10:27:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40395 TP53 SNPs in exon 4 and intron 4 on cancer risk, clinicopathological features and expression of TP53 isoforms. The intron 4 SNPs were significantly over-represented in cohorts of mixed cancers compared to three ethnically matched controls, suggesting they confer increased cancer risk. Further analysis showed that heterozygosity at rs1042522(GC) and either of the two intronic SNPs rs9895829(TC) and rs2909430(AG) confer a 2.34-5.35-fold greater risk of developing cancer. These SNP combinations were found to be associated with shorter patient survival for glioblastoma and prostate cancer. Additionally, these SNPs were associated with tumor-promoting inflammation as evidenced by high levels of infiltrating immune cells and expression of the Δ133TP53 and TP53ß transcripts. We propose that these SNP combinations allow increased expression of the Δ133p53 isoforms to promote the recruitment of immune cells that create an immunosuppressive environment leading to cancer progression.]]> Mon 25 Jul 2022 09:15:39 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47485 Mon 23 Jan 2023 11:48:41 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49526 Mon 22 May 2023 08:31:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37435 Mon 16 Nov 2020 17:39:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54742 Mon 11 Mar 2024 14:26:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44147 Mon 10 Oct 2022 09:17:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48542 Mon 08 May 2023 15:40:54 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46873 7. Overall positive surgical margins (PSM) occurred in 15.9% with pT2 PSM 9.8%, pT3a PSM 30.8% and pT3b PSM 39.2%. Mean urinary continence at 12 months was 91.4% (data available from five surgeons). Mean 12 months potency after bilateral nerve spare was 47.2% (data available from four surgeons). Biochemical recurrence occurred in 10.6% (mean follow up 17 months). Conclusion: The Australian experience of Fellowship trained surgeons performing LRP demonstrates favourable peri-operative, oncological and functional outcomes in comparison to published data for open, laparoscopic and robotic assisted radical prostatectomy. In our Australian centres, LRP remains an acceptable minimally invasive surgical treatment for prostate cancer despite the increasing use of robotic assisted surgery.]]> Mon 05 Dec 2022 09:22:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42619 Mon 04 Sep 2023 13:58:46 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41232 P < 0.001). Conclusion: Only 30% of patients with high-risk features are referred to a radiation oncologist with the likelihood of referral being influenced by the perceived risk of cancer-recurrence as well as the urologist’s institutional/personal preference. When patients are seen by a radiation oncologist, 61% receive radiotherapy within 6 months after RP with the likelihood of receiving radiotherapy not being heavily influenced by increasing risk of recurrence. This suggests many suitable patients would receive radiotherapy if referred and seen by a radiation oncologist.]]> Fri 29 Jul 2022 13:51:38 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52813 Fri 27 Oct 2023 17:01:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33266 Fri 21 Sep 2018 14:23:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52683 Fri 20 Oct 2023 09:51:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42286 Fri 17 Nov 2023 11:23:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42994 Fri 09 Sep 2022 14:03:28 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40341 Fri 08 Jul 2022 10:33:39 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35036 Fri 07 Jun 2019 13:50:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49118 Fri 05 May 2023 11:46:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34907 interaction = -1.3 s, 95% confidence interval [CI] -2.6 to 0.0), whole-body lean mass (ß_interaction = 1194 g, 95% CI 234 to 2153) and ASM mass (ß_interaction = 562 g, 95% CI 49 to 1075), and approached significance for fat mass (ß_interaction = -1107 g, 95% CI -2346 to 132), with greater benefits for men previously on long-term ADT. At 6 months, the intervention effects on chair rise time -1.5 s (95% CI -2.5 to -0.5), whole-body lean mass 824 g (95% CI 8 to 1640), ASM mass 709 g (95% CI 260 to 1158), and fat mass -1377 g (95% CI -2156 to -598) were significant for men previously on long-term ADT, but not for men on short-term ADT. At 12 months, the intervention effects for men on long-term ADT remained significant for the chair rise, with improved performance (-2.0 s, 95% CI -3.0 to -1.0) and increased ASM (537 g, 95% CI 153 to 921). Time on ADT did not moderate the exercise effects on muscle strength, nor did time since ADT cessation moderate any intervention effects. Similarly, testosterone and baseline values of the outcome had negligible moderator effects. Conclusions: Men with PCa previously treated long-term with ADT respond more favourably to exercise in terms of lower body muscle performance and body composition (lean and fat mass, and ASM) than those with short-term ADT exposure. As a result, men who were formerly on long-term androgen suppression regimens should be especially prescribed exercise medicine interventions to alleviate residual treatment-related adverse effects.]]> Fri 01 Apr 2022 09:25:19 AEDT ]]>